Marta Perek-Polnik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1937413/publications.pdf

Version: 2024-02-01

24 papers	2,757 citations	516710 16 h-index	642732 23 g-index
24 all docs	24 docs citations	24 times ranked	4094 citing authors

#	Article	IF	Citations
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
2	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
3	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
4	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
5	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
6	OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas. Journal of Neuropathology and Experimental Neurology, 2006, 65, 176-186.	1.7	68
7	Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. European Journal of Paediatric Neurology, 2012, 16, 83-85.	1.6	62
8	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
9	Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes. Acta Neuropathologica Communications, 2020, 8, 105.	5.2	33
10	Gait pathology assessed with Gillette Gait Index in patients after CNS tumour treatment. Gait and Posture, 2010, 32, 358-362.	1.4	32
11	Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. Acta Neuropathologica, 2010, 119, 325-334.	7.7	30
12	Patterns of failure in children with medulloblastoma treated with 3D conformal radiotherapy. Radiotherapy and Oncology, 2007, 84, 26-33.	0.6	27
13	Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours. Journal of Neuro-Oncology, 2015, 123, 65-73.	2.9	27
14	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
15	Retrospective multiâ€institutional study on hemangiopericytoma in Polish children. Pediatrics International, 2009, 51, 19-24.	0.5	23
16	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
17	Thymic carcinoma in children: A report from the Polish pediatric rare tumors study. Pediatric Blood and Cancer, 2010, 54, 916-920.	1.5	16
18	Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. Journal of Neuro-Oncology, 2018, 138, 231-240.	2.9	16

#	Article	IF	Citations
19	ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients. American Journal of Surgical Pathology, 2017, 41, 781-787.	3.7	14
20	The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies. BMC Cancer, 2017, 17, 239.	2.6	12
21	Functional status of children after treatment for a malignant tumour of the CNS: a preliminary report. Gait and Posture, 2006, 23, 206-210.	1.4	11
22	The frequency of NBN molecular variants in pediatric astrocytic tumors. Journal of Neuro-Oncology, 2010, 96, 161-168.	2.9	11
23	Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors. Brain Tumor Pathology, 2019, 36, 1-6.	1.7	6
24	LINC-08. Neuro-Oncology tumor board â€“ one-year experience of international collaboration. Neuro-Oncology, 2022, 24, i163-i164.	1.2	0